You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Search all journals

Enter search terms…

Advanced search

/

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

Copyright © 2026 by Sage Publications.京ICP备09090397号-11

Search results

Search results page

Articles (9)

Journals (0)

1-9 of 9 results for atezolizumab plus bevacizumab combination therapy

Sort by:

Relevance

Select all

Select all

Sort by:

Relevance

Select article: Prognostic Biomarkers for Hepatocellular Carcinoma Patients Treated With Atezolizumab plus Bevacizumab Combination Therapy

Open access

Review article

First published 2025-04

Prognostic Biomarkers for Hepatocellular Carcinoma Patients Treated With Atezolizumab plus Bevacizumab Combination Therapy

Long-Bin Jeng, Horng-Ren Yang, Chiao-Fang Teng

Cancer Control

Select article: The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma

Retricted access

Article commentary

First published 2022-3

The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma

Jacopo Giuliani, Beatrice Mantoan, Andrea Bonetti

Journal of Oncology Pharmacy Practice

Select article: Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

Open access

Review article

First published 2021

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab

Chiun Hsu, Lorenza Rimassa, Hui-Chuan Sun [...]

Therapeutic Advances in Medical Oncology

Select article: Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Open access

Review article

First published 2021

Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment

Ze-Long Liu, Jing-Hua Liu, Daniel Staiculescu [...]

Therapeutic Advances in Medical Oncology

Select article: Efficacy and safety of a triple combination of atezolizumab,bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter,single-arm,retrospective study

Open access

Research article

First published 2023

Efficacy and safety of a triple combination of atezolizumab,bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter,single-arm,retrospective study

Kang Wang, Zong-Han Liu, Hong-Ming Yu [...]

Therapeutic Advances in Gastroenterology

Select article: Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis

Open access

Research article

First published 2026

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis

Huijie Qi, Yuxin Huang, Wenxin Zhang [...]

Therapeutic Advances in Medical Oncology

Select article: Role of immune checkpoint inhibitor combinations in resectable and unresectable,embolization-eligible hepatocellular carcinoma

Open access

Review article

First published 2025

Role of immune checkpoint inhibitor combinations in resectable and unresectable,embolization-eligible hepatocellular carcinoma

Brandon M. Meyers, Howard J. Lim, Mayur Brahmania [...]

Therapeutic Advances in Medical Oncology

Select article: The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis

Open access

Research article

First published 2024

The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis

Wei Peng, Yangxun Pan, Lan Xie [...]

Therapeutic Advances in Gastroenterology

Select article: First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Open access

Review article

First published 2020-07-02

First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Myuran Thana, Lori Anne Wood

Kidney Cancer

1
10 / page

Article type

Publication date

Subjects

Access